Pazopanib does not bring remarkable improvement in patients with angiosarcoma.

Abstract

Pazopanib is a potent and selective multi-targeted tyrosine kinase inhibitor that has been reported to extend progression-free survival in cases of metastatic soft-tissue sarcoma. However, the efficacy of pazopanib for cutaneous angiosarcoma has not been confirmed. We report eight cases of angiosarcoma treated with pazopanib, and review the efficacy and… (More)
DOI: 10.1111/1346-8138.13558

Topics

Cite this paper

@article{Kitamura2017PazopanibDN, title={Pazopanib does not bring remarkable improvement in patients with angiosarcoma.}, author={Shinya Kitamura and Teruki Yanagi and Yuka Inamura and Hiroo Hata and Keisuke Imafuku and Koji Yoshino and Hiroshi Shimizu}, journal={The Journal of dermatology}, year={2017}, volume={44 1}, pages={64-67} }